Please assess the completion status of the following clinical trial:

Trial Title: Dabigatran Etexilate vs Enoxaparin in Prevention of Venous Thromboembolism (VTE) Post Total Knee Replacement

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria INCLUSION CRITERIA~1. Patients scheduled to undergo a primary, unilateral elective total knee repla cement.~2. Male or female 18 years of age or older.~3. Patients weighing at least 40 kg.~4. Written informed consent prior to the start of study participation.~Exclusion criteria EXCLUSION CRITERIA~1. History of bleeding diathesis.~2. Constitutional or acquired coagulation disorders that in the investigator's judgment puts the patient at excessive risk for bleeding.~3. Major surgery or trauma (e.g. hip fracture) within the last 3 months.~4. Recent unstable cardiovascular disease, such as uncontrolled hypertension at the time of enrollment (investigator's judgment) or history of myocardial infarction within the last 3 months.~5. Spinal or epidural anesthesia, for which more than 3 attempts (sticks) at placement were made, or the placement was traumatic.~   Please note that patients, who are not excluded under this criterion, are to have the catheter pulled at the completion of surgery.~6. Any history of hemorrhagic stroke or any of the following intracranial pathologies: bleeding, neoplasm, arteriovenous (AV) malformation or aneurysm.~7. History of VTE or pre-existing condition requiring anticoagulant therapy.~8. Clinically relevant bleeding (e.g. gastrointestinal, pulmonary, intraocular or urogenital bleeding) within the last 6 months.~9. Gastric or duodenal ulcer within the last 6 months.~10. Liver disease expected to have any potential impact on survival (e.g. hepatitis B or C, cirrhosis, but not Gilbert's syndrome or hepatitis A with complete recovery).~11. Elevated AST or ALT \>2x upper limit of normal, based on central lab results or local lab results within 1 month before enrollment.~12. Known severe renal insufficiency (CrCl \< 30 mL/min). In order to determine patient inclusion/exclusion, creatinine clearance (CrCl) needs to be calculated only if serum creatinine is elevated or renal insufficiency is suspected.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dabigatran Dose 1 (Type: EXPERIMENTAL): low dose regimen taken once daily
- Dabigatran Dose 2 (Type: EXPERIMENTAL): high dose regimen taken once daily
- Enoxaparin (Type: ACTIVE_COMPARATOR): 30 mg subcutaneously twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).